News

Clinical Trials Arena3h
Boehringer and Click seek schizophrenia PDT approval after Phase III success
Boehringer and Click's CT-155 plus antipsychotics significantly reduced negative symptoms associated with schizophrenia in a Phase III trial ...
Clinical Trials Arena21h
Cardiol Therapeutics’ stock down 20% on Phase II CardiolRx failure
Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.
Clinical Trials Arena23h
Eli Lilly’s oral GLP-1RA hits endpoints, but trails Novo’s Wegovy in weight loss
Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.